Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's weird, also this is the fifth straight day of 20,000 plus shares have been sold at bid, concerning..... Hopefully not a foreshadow of us back to fifty
I'll add one more comment that John Hargrove made in the AGM video.
Go to about 28 minutes in and he starts talking about if you have a great technology you need a great team...
28.45 seconds
"we have the capacity to work strategically with the right partners, MORE TO COME ON THAT"
Implying more to come in the future about their strategic partners in the industry..... JNJ/GOOGLE??
Need input on a public level. We saw over 100,000 shares sold today at the bid or the lowest amount a broker is willing to sell at.
Question for the board is this a concern?
So there was over a 100k in sales today at the bid, is that a negative or positive?
Needs the boards help with this ihub app. There is a section on app for trades, and it shows red trades and green trades. Red for sells?? Green for buys?? Today at 14:33:50 there was a trade for 56,100 shares in red, and another for 69,950 in red.
We're these sells?? If someone could give the a,b,c's I would greatly appreciate
Get to Know Your Community: Interview with Stephen Randall, CFO of Titan Medical Inc.
This month, we speak with Stephen Randall, CFO of Titan Medical Inc. (OTCQX: TITXF). The TSX-venture listed company, which trades on OTCQX for its U.S. investors, is focused on the design and development of a robotic surgical system for application in minimally invasive surgery. Mr. Randall talks to us about where the company is in its development cycle, the role of OTCQX in raising additional funding in the U.S. and growth in the global medical robotic systems market.
OTC Markets Group (OTCM): Tell us about Titan Medical. What do you do?
Stephen Randall (SR): Titan Medical is developing a Single Port Orifice Robotic Technology (SPORT™) Surgical System, which is comprised of a surgeon-controlled single incision robotic platform that includes a 3D high definition vision system and interactive instruments for performing minimally invasive surgery (“MIS”) procedures. The surgeon workstation provides the surgeon with an interface to the robotic platform and a 3D endoscopic view of inside a patient’s body during MIS procedures. The SPORT™ Surgical System will enable the surgeon to insert surgical instruments and 3D vision into the patient’s body through a 25 mm skin incision. Once inserted, the device will deploy into a working configuration wherein the 3D vision system and interactive multi-articulating instruments are controlled by a surgeon at the workstation.
OTCM: You have competitors in the market. How will Titan Medical’s robotic surgery technology compare?
SR: Titan’s SPORT™ Surgical System has the following advantages versus competitive systems:
improved dexterity and surgical access;
small architecture providing easy set-up and manoeuvrability;
designed for small space surgery;
an estimated capital cost of less than $1,000,000;
competitive replacement costs for surgical tools; and
a smaller footprint in the operating room.
OTCM: Where are you in the development cycle? When do you expect to reach commercialization?
SR: Titan is on track with respect to its testing phases and is expected to attain all its clinical milestones on schedule. Titan has completed its first major milestone -- the completion of technical feasibility and integrated testing -- and is about to start its second major milestone. The second phase is initiation of pre-clinical and clinical planning process with FDA. The third and fourth phases are CE Mark (European Union) regulatory approval and the commercial launch in the European Union market, respectively. CE Mark approval is expected during 2015 followed by the commercial launch of the product in the European Union later in 2015. The fifth phase, initiation of FDA 510(K) approval, is expected near the end of 2015 with commercialization following quickly thereafter.
OTCM: You recently completed two capital raises. How much did you raise and what do you plan to do with the proceeds?
SR: Titan raised almost U.S. $35 million in two equity raises this spring. These funds will be used to finance the development of Titan’s Single Port Orifice Robotic Technology (SPORT™) Surgical System through to commercialization. Titan has essentially taken all financial risk off the table.
OTCM: Titan Medical joined OTCQX on February 24, 2012. How has OTCQX helped you leverage your existing regulatory filings to globalize your shareholder base?
SR: Approximately 80% of Titan’s investors are American. Listing on the OTCQX has helped Titan to grow and maintain its American shareholder base and attract new investors. In its most recent offerings, Titan was able to raise additional funding in the U.S. Previously, the vast majority of Titan’s funding was raised in Canada.
OTCM: What else should U.S. investors knows about Titan Medical?
SR: The global medical robotic systems market is currently worth $4 billion of which a little more than half consists of Intuitive Surgical, the largest robotic surgery company in the world that is currently marketing its product. The global medical robotic systems market is expected to be worth $20 billion by 2020.
Titan’s development work is being done by Ximedica out of Providence, Rhode Island, a full service ISO 13485 certified and FDA registered product development firm with an exclusive focus on medical products.
Titan Medical Inc. Announces the Formation of Its Surgeon Advisory Board
September 25th, 201X
TORONTO, ONTARIO–(Marketwired – Sept. 25, 201X) – Titan Medical Inc. (“Titan” or the “Company”) (TSX VENTURE: TMD)(OTCQX:TITXF) today announced that it has formed a Surgeon Advisory Board (SAB) that includes seven industry-renowned surgeons who specialize in minimally invasive procedures.
Headed by Dr. Dennis Fowler, Titan’s Executive Vice President, Clinical and Regulatory Affairs, the SAB will assist Titan’s executive management team during the development, pre-clinical testing, and clinical testing of the Single Port Orifice Robotic Technology (SPORT™) Surgical System. Additionally, these surgeons will participate in the development and implementation of a formal training program for the surgical teams who will use SPORT™.
“We are very proud to assemble such an experienced Surgeon Advisory Board, which will be essential in the development and commercialization of SPORT™,” said John Hargrove, Chief Executive Officer of Titan. “All of the Board members are leaders in minimally invasive surgery with a clear understanding of patient benefits and needs. Their profound knowledge and expertise in the space will be invaluable in guiding us through the developmental and testing processes, as well as in positioning SPORT™ in the global market.”
The members of Titan’s Surgeon Advisory Board include:
Arnold Advincula, M.D. is Vice-Chair of Women’s Health & Chief of Gynecology at the Sloane Hospital for Women, Columbia University Medical Center/New York Presbyterian Hospital, and is also Vice-President of the American Association of Gynecologic Laparoscopy (AAGL). He is a leader in minimally invasive surgical techniques and one of the world’s most experienced gynecologic robotic surgeons, and he has both published on and taught these techniques extensively. Dr. Advincula also developed surgical instruments that are in use worldwide.
Juliane Bingener, M.D. is Professor of Surgery and Vice Chair for Quality, Safety and Service in the Department of Surgery in the Mayo Clinic College of Medicine, where she also has a joint appointment in the Division of Gastroenterology and Hepatology. Her clinical and research interests focus on patient reported outcomes and novel technology in the use of minimally invasive surgery and endoscopy for the diagnosis and treatment of gastrointestinal diseases. Dr. Bingener’s previous work included the development of novel Natural Orifice Translumenal Endoscopic Surgery (NOTES) techniques.
Erik Dutson, M.D. is Associate Professor of Surgery and Chief of the Section of Minimally Invasive and Bariatric Surgery at UCLA, where he is also the Executive Medical Director of UCLA’s Center for Advanced Surgical and Interventional Technology (CASIT). His clinical interests include laparoscopic and robotic bariatric surgery, while his research interests focus on the development of computer-assisted technology, such as virtual and augmented reality applications for use in surgical technology.
Adrian Park, M.D. is Chairman of the Department of Surgery and Chair of the Earl Simulation to Advance Innovation and Learning Center of Anne Arundel Health System in Annapolis, Maryland. He is a member of the Board of Directors of the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) and was founding President and Board Chair of the Fellowship Council. His clinical and research focus is on improving minimally invasive surgery and developing new medical devices for complex hernia repair, spleen and adrenal surgery. He is the editor-in-chief of Surgical Innovation, the author of over 200 scholarly articles, and the holder of 20 patents.
Lee L. Swanstrom, M.D. is Chief of the Division of GI and Minimally Invasive Surgery at the Oregon Clinic, Director of Providence Health System’s Complex GI and Foregut Surgery Postgraduate Fellowship Program, and Clinical Professor of Surgery at OHSU. He is a Director of the American Board of Surgery, Past President of both SAGES and the Fellowship Council, and Chief Innovations Officer and Director of the Innovations Fellowship at the Institutes des Hôpitalo Universitaires of the University of Strasbourg, France. His clinical and research focus is on developing innovative approaches to the minimally invasive treatment of foregut and other gastrointestinal disorders. He is editor of Surgical Innovation, the author of over 350 scholarly articles, and holder of 13 patents.
John Valvo, M.D. is Executive Director and the founder of the Robotic and Minimally Invasive Surgery Program at Rochester General Hospital in Rochester, New York and a practicing urologist. Founded in 2004, the program ranks in the top two percent of robotic programs for surgery volume in the United States. The program has trained over 30 robotic surgeons and enabled the completion of more than 7,000 robotic urology, gynecology, general, and colorectal operations. He has authored more than 100 scientific articles including the development of policy guidelines for robotic surgery credentialing.
Yanghee Woo, M.D. is Assistant Professor of Surgery and the Director of the Global Excellence in Gastric Cancer Care at Columbia University Medical Center. She is an upper gastrointestinal surgeon with unique international training in minimally invasive/robotic surgery and has expertise in the surgical treatment of tumors of the stomach, pancreas, small bowel, gallbladder and bile ducts. Dr. Woo is internationally recognized as a leader in robotic surgery for tumors of the stomach and pancreas. She has numerous peer-reviewed publications.
I'll take 65 a share
Under Ximedica’s wing, development of the SPORT™ Surgical System reached critical milestones, including gathering user-needs research, achieving technical feasibility, and performing live-tissue testing in just 15 months.
Development of a pre-production prototype is underway and will be proceeded by preclinical trials, clinical trials, regulatory submission, and a pilot launch.
Titan Medical plans to introduce the SPORT™ Surgical System in Europe and the United States - the world’s two largest markets for robotic surgery.
How nasty game changing would a warren robotics partnership mean to price per share???
I liked these posts made by oral surgeons:
The farther they can carry this on their own, the higher the valuation at time of M&A. An announcement regarding the "worldwide supplier of endomechanical devices" they partnered with has been in an obvious nondisclosure phase for an unknown reason. This could be protocol for stealth reasons and likely others unknown to lay people like myself. That is one of the reasons they past the "Shareholder Protection Plan" to prevent getting bought out on the cheap. Once they announce who they partnered with, all bets are off. If you listen to the AGM video, a lot of what Dr Fowler says sounds like what Google publicly says they are aiming to contribute. If their partner is Warren Robotics, this thing will go through the roof.
that's my bet as well. JNJ jobs listing end effector engineer to work with "outside robotics" company. I bet it's Titan.
well what are they waiting for?
JNJ would be smart to acquire Titan and then let Google do their thing with the Sport shell.
that's my bet as well. JNJ jobs listing end effector engineer to work with "outside robotics" company. I bet it's Titan.
Who would be a likely buyer of Titan?
JNJ would be smart to acquire Titan and then let Google do their thing with the Sport shell.
Actually, according to their most recent financials, Titan currently has no debt...they've been operating solely off of proceeds from the sale of their stock. With a market cap just over $100M right now, I could see an M&A in the $1B range (assuming they're at the technology level at which they claim to be).
Remember, we live in a world where Facebook paid $2B for the pre-market Oculus rift, and where Starbucks paid $100M for La Boulange (which they just recently killed after just two years). Sanity in M&A's has gone out the window, and this will get really interesting if more than one company is interested in buying Titan
Goog/JNJ can then use their ip in the robotic platform they are using
The investment in training has to be huge in order to take business from Intuitive. During earnings they announced an agreement with Anne Arundel Medical Center in developing a training curriculum and performance evaluations for surgeons and surgical teams using the new device.
PLAN OF DISTRIBUTION New Issue We may sell our securities to or through underwriters, dealers, placement agents or other intermediaries and we may also sell our securities directly to purchasers or through agents in negotiated transactions, block trades or a combination of these methods, subject to obtaining any applicable exemption from registration requirements. We may distribute our securities, from time to time, in one or more transactions at a fixed price or prices that may be changed or at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices, including sales in transactions that are deemed to be “at-the-market distributions” as defined in National Instrument 44-102 Shelf Distributions, including sales made directly on the TSX or other existing trading markets for our securities. The prices at which our securities may be offered may vary as between purchasers and during the period of distribution. Any securities offered pursuant to a prospectus supplement by way of at-the- market distributions will be conducted in accordance with applicable securities legislation in Canada and will be subject to regulatory approval. The prospectus supplement relating to each offering of securities will identify each underwriter, dealer or agent, as the case may be, and will also set forth the terms of the offering, including the type of security being offered, the public offering price (or the manner of determination thereof if offered on a non-fixed price basis), the net proceeds to us and any compensation payable to the underwriter, dealers or agents. The Company has provided an undertaking to the Ontario Securities Commission that it will not complete a distribution under a prospectus supplement unless the minimum subscription amount of the distribution, together with the Company’s other resources, is sufficient to achieve one or more development milestones, as set out in this prospectus and further described in the prospectus supplement, together with general and administrative expenses for the period required to achieve such milestones. The Company has also undertaken that the prospectus supplement for any distribution will also include: disclosure regarding the use of proceeds, including but not limited to a description of the principal purposes of the proceeds, including how funds raised under prior distributions under this prospectus have been used or are being allocated, a description of the Company’s business objectives and current development milestones, including the specific time period in which each event is expected to occur and the costs related to it, and a description of the Company’s negative cash flow from operations, if applicable, and to what extent it will use the proceeds of the distribution to fund any anticipated negative cash flow from operating activities in future periods; risk factors relating to the Company and its business, including but not limited to risk factors with respect to cash flow and liquidity, including negative cash flow from operations, if applicable, and the implications of these for the Company’s ability to continue operations and to remain a going concern; disclosure related to the Company’s current financial condition, including but not limited to a description of the Company’s cash on hand at the most recent month end, a description of the Company’s working capital as of a date within 30 days of the date of the prospectus supplement, and a description of the period of time that proceeds of the distribution are expected to fund operations; the estimated length of time in months that the Company could continue operations without raising additional funds; and any other material fact relating to the financial condition of the Company that is required to be included in the prospectus supplement to provide full, true and plain disclosure.
USE OF PROCEEDS Unless otherwise indicated in a prospectus supplement, the Company currently intends to use the net proceeds from the sale of the securities for the manufacture of 11 clinical-grade prototypes of its SPORTTM Surgical System, pre- clinical trial and regulatory costs, and for working capital and other general corporate purposes. Additional funding will be required for the development and commercialization of the SPORTTM Surgical System, currently estimated at approximately U.S. $57 million. At July 31, 2015, the Company had approximately U.S. $16.8 million in cash and cash equivalents and working capital of approximately U.S. $13.8 million. The Company anticipates that it will be able to continue to operate for four months from August 1, 2015 based on the current amount of its cash on hand and short term securities and its current rate of expenditures. The Company expects that approximately U.S. $37 million in incremental funding will be required by the end of 2016 to maintain it’s currently anticipated pace of development. If additional funding is not available, the pace of the Company’s development plan may be reduced. See “Risk Factors”. For the fiscal year ended December 31, 2014, cash used in operating activities by us was U.S. $12,875,254 and we had a net loss of U.S. $ 13,450,261. For the six months ended June 30, 2015, cash used in operating activities by us was U.S. $14,039,599 and we had a net loss of U.S. $17,377,091 for such period. Our working capital as at June 30, 2015 was approximately U.S. $15,100,000. We have not generated any revenue from product sales to date and it is possible that we will never have sufficient product sales revenue to achieve profitability and positive cash flow. We expect to continue to incur losses for at least the next several years as we and our development contractors pursue further development of the SPORTTM Surgical System, clinical trials and research and development efforts. To become profitable, we must successfully develop, manufacture, market and sell the SPORTTM Surgical System, as well as continue to identify, develop, manufacture and market new products. It is possible that we will never have significant product sales revenue. If funding is insufficient at any time in the future, we may not be able to develop or commercialize our products, take advantage of business opportunities or respond to competitive pressures. It is expected that proceeds of distributions of securities under this prospectus will be used to fund anticipated negative cash flow from operating activities, as described above. More detailed information regarding the use of proceeds from the sale of securities will be described in the applicable prospectus supplement. Pending the application of the net proceeds, the Company intends to invest substantially all of the net proceeds in term deposits and high interest savings accounts with a major Canadian chartered bank, or in investment-grade, interest-bearing securities, the primary objectives of which are liquidity and capital preservation.
Market correction coming
Pump hype bs no reason to believe you go pump a failing stock elsewhere
$TITXF Take note of the brunette hair lady, not only because she's attractive, but because...
Hope it's an announcement that Johnson and Johnson Innovation has partnered with Titan medical
http://www.jjdevcorp.com/competitive-advantages
JJDC Competitive Advantage Johnson & Johnson Development Corporation (JJDC) is interested in products, services, and technologies that have large addressable markets with clearly defined competitive advantages and IP protection. Venture investments must be backed by an executable clinical and commercialization plan with a clear path to defining and sustaining a leading market position and leveraging competitive advantages to accelerate market adoption and revenue growth.
The question is answered at 1:34 into meeting, I found it interesting how jnj analyst talks about making the robotic platform more mobile and using a smaller footprint in the operating room
Why Samsung Is Partnering Up with This Healthcare Company
Samsung is following Apple into the wearables market by partnering with this healthcare giant. Will the partnership move the needle for either company?
Brian Feroldi
Jun 28, 2015 at 9:43AM
Consumer electronics juggernaut Samsung Electronics Co. (NASDAQ Other:SSNLF) and medical device powerhouse Medtronic PLC (NYSE:MDT) have been in the news recently after they announced a joint partnership at the American Diabetes Association 75th Scientific Sessions. The goal of the partnership is to combine each of their areas of expertise to make it easier for people with diabetes to successfully manage their disease. The companies have stated their intentions to develop a range of future solutions that will allow for patients with diabetes to have easier access to viewing their data, with the ultimate goal of fully integrating mobile and wearable devices into a complete diabetes management system.
For Samsung, this partnership will provide a foot in the door in the important health-related wearables market, as they are desperately trying to keep pace with Apple. Apple is pushing hard to be an important player in the space, as is evident from the company's recent product launches like Health Kit, Research Kit, and the Apple Watch. Establishing a direct relationship with a medical device giant like Medtronic appears to be a sound strategy for carving out a space in the market.
This deal also makes a lot of sense for Medtronic, as Samsung is a huge player in the consumer electronics market, and it's likely that a huge number of patients using Medtronic's devices already have a Samsung device. Medtronic is currently a huge player in the diabetes device market -- the company rang up more than $1.6 billion in sales in 2014 from the sale of its insulin pump and continuous glucose monitoring devices.
In a separate but related announcement, Medtronic also stated that it received FDA approval for the MiniMed Connect. The Connect consists of a small uploader device that allows for data from Medtronic's insulin pump or continuous glucose sensor to talk directly to a mobile phone. This data can then be viewed directly on the phone itself or relayed to the cloud for viewing on a variety of Internet-enabled devices. Once in the cloud the data could then be shared with a variety of healthcare providers like family members, school nurses, or physicians.
The Minimed Connect will go on sale for $199 this fall, and will initially be rolled out on only to iOS devices like the iPhone and iPod touch in the U.S. Medtronic did mention they plan to make the device available for Android users as well, and the company is planning on taking additional steps with Samsung mobile devices specifically, which includes developing their custom own app to optimize the experience.
If this idea sounds familiar, it should, as Medtronic's smaller but faster growing glucose sensor rival Dexcom (NASDAQ:DXCM) recently launched a similar product. The Dexcom G4 Platinum with Share went on sale earlier this year, and the device allows for Dexcom's receiver device to communicate with Apple's iOS product directly. Dexcom's system doesn't require a separate uploader like Medtronic does, and Dexcom's system is already integrated into the Apple Watch as well.
However, Medtronic's device may be more useful to providers than Dexcom's currently is, as the Connect will share insulin pump related data as well. Perhaps that extra data will be enough of an advantage to entice their users to carry yet another device on them all the time.
Reading the wired article about jnj and Google partnership, looks like Googles role will be with software.....
In that surgical products article it quotes fowler
"All of the other advances are going to be software related,” he explained. “They will focus on automation and navigation to enable the computer assisted surgical device to help surgeons do better operations. All of that will be available through software upgrades on the platform. That’s how we anticipate that it will be improved over time.”
Did we find the missing link!!!! Is this a foreshadow to our buyout partner???????
Google Titan medical .....
Notice two locations???????
One location on university ave named "robotic components"
Another location on tradewinds Ave named "surgical supply tools"
Press release about telesurgery from Titan back in 2009...
Titan Medical Inc. (TSX VENTURE:TMD) and Bell Canada (TSX:BCE) announced today that they have successfully completed telesurgery tests using Titan Medical?s Phase B Amadeus®, a next generation robotic surgical system. During a one-week testing period, the tests were done over an unprecedented long distance spanning roundtrip from Toronto to Vancouver, Canada. The total communications distance was approximately 7,000 km.
TORONTO, ONTARIO (Marketwire ? March 17, 2009) ? Titan Medical Inc. (TSX
VENTURE:TMD) and Bell Canada (TSX:BCE) announced today that they have
successfully completed telesurgery tests using Titan Medical?s Phase B Amadeus®,
a next generation robotic surgical system. During a one-week testing period, the
tests were done over an unprecedented long distance spanning roundtrip from
Toronto to Vancouver, Canada. The total communications distance was
approximately 7,000 km.
Telesurgery is the performance of robotic surgery over a distance using a
communication link. Transmitting low latency dual high definition signals for
three dimensional vision and instrument commands with minimal time lag (or
latency) were critical. Total end-to-end latency was approximately 300 ms, and
will be expected to shorten when the Phase C clinical testing platform is completed.
Dr. Reiza Rayman, President of Titan Medical Inc., commented as follows:
?The concept of long distance remote control can bear many benefits. An increase
in the surgeons? range of ?ability to operate? will bring their expertise to a
greater number of patients. Expert collaborations and procedural training will
be simpler, quicker, and more effective. Patient transportation costs will
decrease. Under-serviced communities can be supported by established hospitals.
Surgeons will be removed from harm of a battlefield in military applications.?
The extreme distances in these tests were implemented to generate worst-case
scenario data. ?In day-to-day applications, we expect the distances to be much
shorter. These will likely be between neighbouring cities, a tertiary hospital
catchment area or proximate offshore locations,? commented Dr. Rayman.
Previous research has shown that 350 ms or less latency is required for surgeons
to effectively perform telesurgery. Additionally, the amount of bandwidth needed
to transmit the high definition video is being analyzed. Specific data on
latency and bandwidth results of these tests will be published shortly in a full
White Paper.
Stéphane Boisvert, President of Bell Canada?s Enterprise Group, said the tests
are an important next step in the evolution of telesurgery that Bell has
supported for several years. ?We have proven in the past that the quality of the
Bell network can support telesurgery over shorter distances, such as from
Hamilton to Sudbury. But thanks to these tests we are now seeing the very real
potential of telesurgery over much greater distances. That means significant
benefits for more patients, for caregivers and for the economics of our health
care system as a whole, all of which are critically important to the quality of
life Canadians enjoy.?
About Telesurgery: Telesurgery is when a surgeon in one location ? using remote
controlled robotics and state-of-the-art communications networks ? performs
surgery on a patient from a different location. Telesurgery is a combination of
advanced elements of robotics, communication technologies and management
information systems. Currently in the field of robotic surgery, most robots are
controlled by surgeons at the location of the surgery.
Telesurgery, on the other hand, offers the promise for patients to have access
to surgeons from around the world, without the need for patients to travel
beyond their local hospital for surgery.
About Bell Canada
Bell is Canada's largest communications company, providing consumers with
solutions to all their communications needs, including telephone services,
wireless communications, high-speed Internet, digital television and voice over
IP. Bell also offers integrated information and communications technology (ICT)
services to businesses and governments, and is the Virtual Chief Information
Officer (VCIO) to small and medium businesses (SMBs). Bell is proud to be a
Premier National Partner and the exclusive Telecommunications Partner to the
Vancouver 2010 Olympic and Paralympic Winter Games. Bell is wholly owned by BCE
Inc. For information on Bell's products and services, please visit www.bell.ca.
For corporate information on BCE, please visit www.bce.ca.
About Titan Medical Inc.
Titan Medical Inc. is a Canadian public company (TSX VENTURE:TMD) focused on the
development and commercialization of robotic surgical technologies. The Company
is currently developing Amadeus®, a next generation 4-armed robotic surgical
system, with the objective of enabling surgeons to remotely manipulate surgical
instruments. Robotic surgery has developed over the past 10 years into a proven
and growing method of treatment. The global robotic surgical market size is
currently estimated to be $3.4 billion with potential for placement of 6,000
robotic surgical systems. The Company is researching and developing innovative
technologies to empower surgeons to use robots in the operating room of the
future. For more information, visit the Company?s website at
www.titanmedicalinc.com.
The TSX Venture Exchange does not accept responsibility for the adequacy or
accuracy of this release.
That's exactly my guess everytime I go to watch that video It reminds me of the days of aol 95 when it too five minutes jest to get online
Website back up
Titans website down..... I'm getting Bandwidth Limit Exceeded error message
Surgical robots represent the best of innovation; they improve surgical outcomes for patients. In that sense, they can aid surgeons but not replace them. They may reduce patient blood loss and post-operative pain by allowing surgeons to operate – especially with minimally invasive surgeries – with even greater precision.
Video does not play on website currently
I liked the scene at the end of the video with the surgeon and his 3-d glasses
SurgiSlut is taking robotic surgery to a game changing scary next level
Looks like another company long term gems would invest heavily in
http://www.transenterix.com/technology/surgibot/
Anyone see the exact same product??
http://mst-sys.com
Question regarding capital gains
I am a newbie and this may be a stupid question...
Say I have a friend who has been buying Titan for last two years. He's accumulated over 10k shares
He buys 1k shares tomorrow at 1.35. A month from now shares jump to 2.35 he sells a 1k shares.
At the sell, is this considered a longterm or shorterm capital gain??
Tele Surgery is what blows my mind
CUIN are you for real? Your crystal ball told you to sell at 2.50 and you played piss pot told you so for three months.
Shut the front door and don't take anyone with you
You won't be missed go have an ecig with your laser therapy
Cuin really? "ur seriously contemplating exiting as soon as reasonably possible"
I trust that your a verified flake
Go pump ecig and get at theralese cancer treatment you hack
27.4 million cash on hand
3.6 million a month burn rate
7 months before ...
M & A : Medtronic
1:1 share
Merger share price 77.81
TopCat how soon until a buyout occurs in your opinion?
Let's take the conversation to the opportunity for shareholders to buy significant discounted shares
If a take-over bid does not meet the Permitted Bid requirements of the Plan, the rights will entitle shareholders, excluding the shareholder or shareholders making the take-over bid, to purchase additional common shares of the Company at a substantial discount to the market price of the common shares at that time.
Let's take the conversation to the opportunity for shareholders to buy significant discounted shares
If a take-over bid does not meet the Permitted Bid requirements of the Plan, the rights will entitle shareholders, excluding the shareholder or shareholders making the take-over bid, to purchase additional common shares of the Company at a substantial discount to the market price of the common shares at that time.
Google Robotic Surgery Company
Then do it on Yahoo, and Bing.
Anyone seeing a theme here?
Google is getting sued overseas bung the EU because how they favorably rank thier products to top of search...
I am connecting dots here but Google ranks Titan medical as the number one ranking result, as does yahoo and bing hmmmmmmm
Does anyone have any insight behind this?
This link goes back to the bloomburg Titan Medical Inc
(QTN:German Stock Exchange) board members page..
http://www.bloomberg.com/research/stocks/people/board.asp?ticker=QTN:GR
Look to "Other Board Members On Board"
Who are these other board members that bloomberg is referring to?
Note David Albala M.D.
Martin Bernholtz BBA,CA,ARP
Bob Kiaii M.D.
W. Boyd M.D., MEd
Hiep Nguyen M.D.
David Albala M.D. ->Member of Advisory Board, TransEnterix, Inc.
Po Lam M.D.
Louis Eichel M.D.
Carlo Passerotti M.D., Ph.D.
Li-Ming Su M.D.
Eric Moore M.D.
Sivakumar Balasubramanian M.D.
Terry Grogg M.D.
Bruce Wolff M.D.